Bod Australia

What Bod Australia does

Bod Australia (ASX: BOD) is a Sydney-based, publicly listed medicinal cannabis company founded in 2016 that develops, supplies, and clinically researches prescription-only cannabinoid-based medicines for the Australian market. The company's core product is Bod MediCabilis, supplemented by a portfolio of medicinal cannabis formulations across multiple delivery formats including oils (the dominant delivery method), capsules, dry flower, oromucosal spray, lozenges, and creams. Bod invests in clinical research across seven therapeutic indications — chronic pain, anxiety, stress, depression, epilepsy, arthritis, and inflammation — and is actively recruiting participants for the CAN-REST insomnia study using cannabinoid-based medications.

The company operates a B2B2C distribution model in which licensed pharmacies order Bod's prescription cannabis products directly upon receipt of approved prescriptions, while partner medical clinics assess patient eligibility and issue prescriptions through a doctor support program. Bod generates revenue primarily through prescription medicinal cannabis sales priced at the pharmacy level, with pricing not publicly disclosed. The company is headquartered in Australia, employs 11-50 people, and serves two primary customer segments: patients with chronic conditions seeking cannabinoid-based treatment after standard options have been exhausted, and the healthcare professionals (doctors and clinic partners) who prescribe these treatments.

From a corporate governance and operational perspective, Bod Australia is led by founder and CEO Jo Patterson, CFO Adrian Sturrock, and CTO Craig Weller. The business is positioned at the intersection of regulated pharmaceutical distribution, clinical evidence generation, and prescriber education within Australia's controlled medicinal cannabis framework, with no disclosed AI or proprietary technology platform beyond its pharmaceutical formulations and pharmacy ordering infrastructure.

Name

Bod Australia

Legal name

Bod Australia

Website

https://bodaustralia.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Bod Australia (ASX: BOD) is a Sydney-based, publicly listed medicinal cannabis company that supplies prescription-only cannabinoid medicines including Bod MediCabilis to Australian pharmacies and clinics, serving patients with chronic conditions across seven therapeutic indications.

Ownership category

akta.pro rank

Product category

Medicinal Cannabis Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Medical Cannabis Dispensaries (CRANAFAB)

akta.pro secondary industry

CBD/Hemp Wellness & Supplements Retail (CRANAHAC)

Keywords

• Medicinal cannabis products
• Prescription pharmaceuticals
• Cannabinoid-based medicine
• Clinical research services
• Herbal healthcare

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Prescription Medicinal Cannabis Sales: Bod Science generates revenue through the sale of prescription-only medicinal cannabis products, primarily Bod MediCabilis, distributed through pharmacies. Healthcare providers prescribe the medication after patient assessment, and pharmacies order directly from Bod upon receiving approved prescriptions.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Bod Australia develops, manufactures, and distributes prescription-only medicinal cannabis products under the Bod Science brand, with Bod MediCabilis as the flagship prescription medicine offered in multiple delivery formats including oils, capsules, dry flower, oromucosal sprays, lozenges, and creams. The company also conducts clinical research on cannabinoid-based therapies, including the CAN-REST study for chronic insomnia, and distributes its products through a national pharmacy network of more than 3,000 locations in Australia.

Product overview

Bod Australia operates as a medicinal cannabis company offering a portfolio of prescription-only cannabis-based medicines. The core product is Bod MediCabilis, supplemented by a range of medicinal cannabis delivery formats including oils, capsules, dry flower, oromucosal spray, lozenges, and creams. The company also conducts clinical trials and research (such as the CAN-REST insomnia study) and provides doctor support services to facilitate patient access to medicinal cannabis treatments for chronic conditions.

Differentiator

Problem solved

Functional benefit

Brands

• Bod MediCabilis: Prescription-only medicinal cannabis medicine offered by the company through pharmacy ordering.

Products and services

• Bod MediCabilis
• Medicinal Cannabis Product Range A range of Bod MediCabilis medicinal cannabis delivery formats — oils, capsules, dry flower, oromucosal sprays, lozenges, and creams — manufactured and supplied to Australian pharmacies to meet varied patient and prescriber preferences.
• Clinical Trials and Research Services Clinical research conducted by Bod Science, including the CAN-REST trial evaluating medicinal cannabis for chronic insomnia, generating clinical evidence to support prescribing and product claims.

Quantifiable outcome

• Medicinal cannabis can be prescribed for any chronic indication where supporting clinical evidence exists

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Pharmacy PartnerscoreChannel Partner/ Reseller/ DistributorBod Science maintains direct relationships with pharmacies across Australia that dispense Bod MediCabilis and other medicinal cannabis products. Pharmacies order directly from Bod once prescriptions are approved and received, creating a streamlined distribution channel.
• Medical ClinicscoreStrategic or Co-development PartnerPartner medical clinics assess patient eligibility and prescribe medicinal cannabis treatments. The company supports these clinical partners through its doctor support program, providing educational resources and expert care coordination for patients seeking cannabinoid-based treatments.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Little Green Pharma: ASX-listed Australian medicinal cannabis manufacturer and distributor offering a comparable range of cannabis oil and flower products through pharmacy channels, directly competing with Bod MediCabilis for the same prescriber base.
• Cann Group: Australian licensed medicinal cannabis producer (ASX: CAN) supplying cultivated and manufactured cannabis products to patients via prescription — overlapping with Bod's product portfolio and pharmacy distribution model.
• Auscann Group Holdings: ASX-listed Australian medicinal cannabis company developing and supplying cannabinoid-based pharmaceutical products for human and animal health, competing in the same domestic prescription cannabis market as Bod.
• THC Global Group: Australian medicinal cannabis manufacturer with pharmacy-distributed product lines, including oils and capsules, directly overlapping with Bod's prescription cannabis offering and distribution model.
• Althea Group: Australian medicinal cannabis company historically operating a similar pharmacy-distributed, prescriber-education-driven model to Bod, with overlapping product formats (oils, flowers) and chronic-condition therapeutic focus.

Emerging players

• Incannex Healthcare: ASX-listed clinical-stage Australian cannabinoid and psychedelic medicine developer. Overlaps with Bod in cannabinoid-based prescription therapeutics and clinical research focus, though targeting different product formats (e.g., psilocybin plus CBD combinations).
• Zelira Therapeutics: Australia-based (ASX: ZLD) cannabinoid medicine company with clinical programs across insomnia, pain, and other indications, overlapping with Bod's research-driven commercial strategy and prescription product positioning.

Broad incumbents

• Tilray Brands: Global large-scale cannabis producer with established Australian distribution. Offers a much broader portfolio of medical and recreational cannabis products, applying scale and capital advantages that pressure smaller Australian players like Bod.
• Jazz Pharmaceuticals (GW Pharmaceuticals): Owner of the pioneering cannabinoid pharmaceutical Sativex and Epidiolex, representing a global regulatory and clinical benchmark for prescription cannabis medicines that frames the competitive ceiling for companies like Bod.

Others

• IDT Australia: ASX-listed Australian pharmaceutical manufacturer providing contract manufacturing and formulation services relevant to the medicinal cannabis supply chain — adjacent infrastructure rather than a direct competitor, but comparable as an Australian pharma platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/bodaustralia

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bod Australia